TNFRSF11B, OCIF, OPG, Osteoprotegerin
Recombinant Human TNFRSF11B /Osteoprotegerin Protein,C-Fc Tag,HEK293 expressed (rh TNFRSF11B Fc Chimera) Glu 22 - Leu 401 (Accession # NP_002537) was produced in human 293 cells (HEK293) at ACRObiosystems.
rh TNFRSF11B Fc Chimera, fused with Fc fragment of human IgG1 at the C-terminus, has a calculated MW of 70.2 kDa. The predicted N-terminus is Glu 22. As a result of glycosylation, DTT-reduced Protein migrates as 66-85 kDa and non-reduced protein migrates as 130-170 kDa.
Less than 1.0 EU per μg of the rh TNFRSF11B Fc Chimera by the LAL method.
>92% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM tris, 100 mM glycine, pH7.5. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product format or formulation.
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC).
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) is also known as Osteoclastogenesis inhibitory factor (OCIF), Osteoprotegerin (OPG). TNFRSF11B is a secreted homodimer protein, which can interact with TNFSF10 and TNFSF11. TNFRSF11B acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. TNFRSF11B inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.